Blinatumomab: all 129 studies that test it
Page 2 of 2. Open to participants first (58), then studies with results posted, then the rest; newest registration first within each.
- Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingNCT04722848Phase 3
- Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)Status unknownNCT04604691Phase 1
- Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)CompletedNCT04554485Phase 2
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsActive, not recruitingNCT04530565Phase 3
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Phase 1/2
- Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALLWithdrawnNCT04448834Phase 2
- Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaActive, not recruitingNCT04329325Phase 2
- Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell TransplantTerminatedNCT04044560Phase 2
- BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter TransformationCompletedNCT03931642Phase 2
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaActive, not recruitingNCT03914625Phase 3
- Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALLCompletedNCT03751709Phase 1
- Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic LeukemiaActive, not recruitingNCT03709719Phase 2
- Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or LymphomaWithdrawnNCT03605589Phase 1
- Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.Active, not recruitingNCT03541083Phase 2
- PETHEMA-BLIN-01/PET069014 (BLIN-01)TerminatedNCT03523429Phase 2
- Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaActive, not recruitingNCT03512405Phase 1/2
- Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and BlinatumomabCompletedNCT03480438Phase 2
- Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic LeukemiaCompletedNCT03367299Phase 2
- Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple MyelomaTerminatedNCT03173430Early Phase 1
- Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaActive, not recruitingNCT03147612Phase 2
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
- A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission MaintenanceActive, not recruitingNCT03114865Phase 1/2
- Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic LeukemiaCompletedNCT03109093Phase 2
- Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT03072771Phase 1
- Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior TransplantationActive, not recruitingNCT02790515Phase 2
- D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic LeukemiaStatus unknownNCT02744768Phase 2
- Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT02568553Phase 1
- A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT00676871Phase 1/2
- A Phase I Study to Evaluate Safety, Tolerability in Adults With LymphomaWithdrawnNCT00538096Phase 1